Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PABPC1 | P11940 | 1/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 4/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6217663 | 1.00 | PABPC1 (0.50) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| SCHEMBL6218973 | 0.98 | PABPC1 (0.53) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| SCHEMBL24079288 | 0.91 | — | — | |
| SCHEMBL13381093 | 0.80 | PABPC1 (0.56) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| SCHEMBL6580747 | 0.78 | GAA (0.50) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| SCHEMBL18885118 | 0.78 | PABPC1 (0.59) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| SCHEMBL6218416 | 0.78 | GAA (0.50) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| SCHEMBL13381099 | 0.78 | PABPC1 (0.59) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| SCHEMBL1487109 | 0.77 | PABPC1 (0.53) | PABPC1CTDSP1GAATMEM97SIGMAR1 | |
| SCHEMBL8192982 | 0.77 | PABPC1 (0.53) | PABPC1CTDSP1GAATMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6835734-B2 | (S)-3-(4-Phenyl-1-piperazinyl)-1,2-propanediol cyclic acetals, useful as intermediates for the preparation of levodropropizine | Dompé S.p.A. (IT) | 2004-12-28 | — | — | US | disclosed |
| EP-1307441-B1 | 1,3-DIOXOLANES WITH ANTITUSSIVE ACTIVITY | DOMPE SPA (IT) | 2004-05-06 | — | — | EP | disclosed |
| US-20040038989-A1 | 1,3-dioxolanes with antitussive activity | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2004-02-26 | — | — | US | disclosed |
| EP-1307441-A1 | 1,3-DIOXOLANES WITH ANTITUSSIVE ACTIVITY | Dompe' S.P.A. (IT) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002010149-A1 | 1,3-DIOXOLANES WITH ANTITUSSIVE ACTIVITY | DOMPE' S.P.A. (IT) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038989-A1 | 1,3-dioxolanes with antitussive activity | ADRA1D, QDPR, PDE3A | PABPC1 1032/4885CTDSP1 1104/4885GAA 3620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.